Daewoong saw the highest growth of 156% in patent filings in October and 299% in grants in December in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 156% and grants by 56%. GlobalData’s DataBook provides a comprehensive analysis of Daewoong’s patent filings and grants. Buy the databook here.
Daewoong has been focused on protecting inventions in South Korea(KR) with 13 publications in Q4 2023
The South Korea(KR) Patent Office dominates the patent filings and grants with nearly 32% filings and 62% grants. The South Korea(KR), World Intellectual Property Organization(WIPO), Australia(AU), and Brazil(BR) patent Office are among the top ten patent offices where Daewoong is filings its patents. Among the top granted patent authorities, Daewoong has 62% of its grants in South Korea(KR), 25% in Japan(JP) and 12% in Brazil(BR).
Pfizer could be the strongest competitor for Daewoong
Patents related to rare diseases and climate change lead Daewoong's portfolio
Daewoong has the highest number of patents in rare diseases followed by, climate change and health & wellness. For rare diseases, nearly 50% of patents were filed and no patents were granted in Q4 2023.
Fibrosis related patents lead Daewoong portfolio followed by food, and drug delivery devices
Daewoong has highest number of patents in fibrosis followed by food, drug delivery devices, diabetes, and manufacturing/industrial.
For comprehensive analysis of Daewoong's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.